Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 58-63

  Kang, Sokbom ^a   Dong, Seung Myung ^a   Park, Noh Hyun ^b  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Biomarker; Diagnosis; DNA hypermethylation; Epigenetics; Microarray; Ovarian cancer; TGFBI; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CISPLATIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INHIBITION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENTIATION; EPIGENETICS; FEMALE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS SPECTROMETRY; METHYLATION; MICROARRAY ANALYSIS; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA INDUCIBLE GENE H3; TUMOR GENE;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CELL LINE, TUMOR; DNA METHYLATION; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77953287973     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.025     Document Type: Article

References (46)

1. Feinberg A.P., and Tycko B. The history of cancer epigenetics. Nat Rev Cancer 4 (2004) 143-153
2. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 4 (2004) 988-993
3. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
4. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 16 (2002) 6-21
5. Hatada I., Hayashizaki Y., Hirotsune S., Komatsubara H., and Mukai T. A genomic scanning method for higher organisms using restriction sites as landmarks. Proc Natl Acad Sci U S A 88 (1991) 9523-9527
6. Lisitsyn N., Lisitsyn N., and Wigler M. Cloning the differences between two complex genomes. Science 259 (1993) 946-951
7. Welsh J., and McClelland M. Genomic fingerprinting using arbitrarily primed PCR and a matrix of pairwise combinations of primers. Nucleic Acids Res 19 (1991) 5275-5279
8. Foltz G., Ryu G.Y., Yoon J.G., Nelson T., Fahey J., and Frakes A. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 66 (2006) 6665-6674
9. Kim M.S., Yamashita K., Baek J.H., Park H.L., Carvalho A.L., Osada M., et al. N-methyl-d-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66 (2006) 3409-3418
10. Kim T.Y., Zhong S., Fields C.R., Kim J.H., and Robertson K.D. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 66 (2006) 7490-7501
11. Muthusamy V., Duraisamy S., Bradbury C.M., Hobbs C., Curley D.P., Nelson B., et al. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66 (2006) 11187-11193
12. Sato N., Fukushima N., Chang R., Matsubayashi H., and Goggins M. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 130 (2006) 548-565
13. Shi H., Guo J., Duff D.J., Rahmatpanah F., Chitima-Matsiga R., Al-Kuhlani M., et al. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 28 (2007) 60-70
14. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
15. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
16. Mhawech P., Benz A., Cerato C., Greloz V., Assaly M., Desmond J.C., et al. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 18 (2005) 340-348
17. Kaneuchi M., Sasaki M., Tanaka Y., Shiina H., Verma M., Ebina Y., et al. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316 (2004) 1156-1162
18. Akahira J., Sugihashi Y., Suzuki T., Ito K., Niikura H., Moriya T., et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10 (2004) 2687-2693
19. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 3 (2003) 931-943
20. Strathdee G., MacKean M.J., Illand M., and Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18 (1999) 2335-2341
21. Ferguson A.T., Evron E., Umbricht C.B., Pandita T.K., Chan T.A., Hermeking H., et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 97 (2000) 6049-6054
22. Osada H., Tatematsu Y., Yatabe Y., Nakagawa T., Konishi H., Harano T., et al. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 21 (2002) 2418-2424
23. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H., and Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60 (2000) 4353-4357
24. Shao G., Berenguer J., Borczuk A.C., Powell C.A., Hei T.K., and Zhao Y. Epigenetic inactivation of Betaig-h3 gene in human cancer cells. Cancer Res 66 (2006) 4566-4573
25. Skonier J., Neubauer M., Madisen L., Bennett K., Plowman G.D., and Purchio A.F. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 11 (1992) 511-522
26. Skonier J., Bennett K., Rothwell V., Kosowski S., Plowman G., Wallace P., et al. beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 13 (1994) 571-584
27. Stone E.M., Mathers W.D., Rosenwasser G.O., Holland E.J., Folberg R., Krachmer J.H., et al. Three autosomal dominant corneal dystrophies map to chromosome 5q. Nat Genet 6 (1994) 47-51
28. Hanssen E., Reinboth B., and Gibson M.A. Covalent and non-covalent interactions of betaig-h3 with collagen VI. Beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils. J Biol Chem 278 (2003) 24334-24341
29. Hashimoto K., Noshiro M., Ohno S., Kawamoto T., Satakeda H., Akagawa Y., et al. Characterization of a cartilage-derived 66-kDa protein (RGD-CAP/beta ig-h3) that binds to collagen. Biochim Biophys Acta 1355 (1997) 303-314
30. Zhao Y., El-Gabry M., and Hei T.K. Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog 45 (2006) 84-92
31. Billings P.C., Whitbeck J.C., Adams C.S., Abrams W.R., Cohen A.J., Engelsberg B.N., et al. The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem 277 (2002) 28003-28009
32. Kim J.E., Jeong H.W., Nam J.O., Lee B.H., Choi J.Y., Park R.W., et al. Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem 277 (2002) 46159-46165
33. Rathi A., Virmani A.K., Schorge J.O., Elias K.J., Maruyama R., Minna J.D., et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8 (2002) 3324-3331
34. Katsaros D., Cho W., Singal R., Fracchioli S., Rigault De La Longrais I.A., Arisio R., et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94 (2004) 685-692
35. Makarla P.B., Saboorian M.H., Ashfaq R., Toyooka K.O., Toyooka S., Minna J.D., et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11 (2005) 5365-5369
36. Olopade O.I., and Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3 (2003) 417-420
37. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10 (2004) 4420-4426
38. Tokumaru Y., Harden S.V., Sun D.I., Yamashita K., Epstein J.I., and Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10 (2004) 5518-5522
39. Topaloglu O., Hoque M.O., Tokumaru Y., Lee J., Ratovitski E., Sidransky D., et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10 (2004) 2284-2288
40. Wiley A., Katsaros D., Chen H., Rigault de la Longrais I.A., Beeghly A., Puopolo M., et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107 (2006) 299-308
41. Wang C., Horiuchi A., Imai T., Ohira S., Itoh K., Nikaido T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202 (2004) 215-223
42. Zhao Y.L., Piao C.Q., and Hei T.K. Overexpression of Betaig-h3 gene downregulates integrin alpha5beta1 and suppresses tumorigenicity in radiation-induced tumorigenic human bronchial epithelial cells. Br J Cancer 86 (2002) 1923-1928
43. Zhao Y.L., Piao C.Q., and Hei T.K. Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 21 (2002) 7471-7477
44. Nam J.O., Jeong H.W., Lee B.H., Park R.W., and Kim I.S. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin. Cancer Res 65 (2005) 4153-4161
45. Becker J., Erdlenbruch B., Noskova I., Schramm A., Aumailley M., Schorderet D.F., et al. Keratoepithelin suppresses the progression of experimental human neuroblastomas. Cancer Res 66 (2006) 5314-5321
46. Ahmed A.A., Mills A.D., Ibrahim A.E., Temple J., Blenkiron C., Vias M., et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12 (2007) 514-527